Emideltide official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
Different proposed uses have different evidence gaps
FDA’s July 2026 briefing assessed chronic insomnia, narcolepsy and opioid withdrawal separately. Small heterogeneous sleep studies and a single-person narcolepsy report did not establish durable clinical benefit. FDA PDF pp. 32, 33, 34, 36 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Withdrawal reports lacked robust controls
FDA described small open-label studies with no comparison group, inconsistent outcome methods and limited completion. Apparent short-term changes do not establish an effective maintenance treatment. FDA PDF pp. 38, 39 ↗
The route mismatch is material
The clinical reports discussed intravenous administration, while the nomination proposed subcutaneous use. FDA reported no safety data for that proposed route and insufficient characterization of chronic intermittent use. FDA PDF pp. 53, 56 ↗
A briefing proposal is not a final decision
FDA staff proposed against adding the nominated substances to the 503A bulks list, citing quality, effectiveness and safety gaps. The document explicitly precedes the final agency determination. FDA PDF pp. 1, 53, 56 ↗
What remains to be checked
- Check subsequent advisory records and any final FDA action separately from the staff briefing.
- Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
FDA emideltide briefing for the July 2026 advisory meeting ↗
Source dated 2026-07-23; retrieved 2026-09-19.
- Different proposed uses have different evidence gaps · PDF pp. 32, 33, 34, 36 of 83
- Withdrawal reports lacked robust controls · PDF pp. 38, 39 of 83
- The route mismatch is material · PDF pp. 53, 56 of 83
- A briefing proposal is not a final decision · PDF pp. 1, 53, 56 of 83
SHA-256:
6753532d72dd9366e35a5c3669ce7b2a6ffb6edbceac0ca4c963b1703f392906